FDA Announces Recall

There has been a Correction Issued by Medline for Kits Containing Huons Lidocaine Hydrochloride and Bupivacaine Hydrochloride in Dextrose Injection.

The FDA is aware that Medline has issued a letter to affected customers recommending certain convenience kits be corrected prior to continued use by removing included Lidocaine Hydrochloride and Bupivacaine Hydrochloride in Dextrose Injections.

Medline Industries is removing Huons Lidocaine Hydrochloride Injection and Bupivacaine Hydrochloride in Dextrose Injection from certain convenience kits. Huons Co., Ltd. initiated a recall of Lidocaine Hydrochloride Injection and Bupivacaine HCL in Dextrose Injection following a recent FDA inspection of its manufacturing facility, which identified quality issues. Use of lidocaine and bupivacaine product with reduced anesthetic effectiveness may result in ineffective pain control, procedural discomfort, or repeat or delayed treatment.

As of May 20, Medline has reported no serious injuries and deaths associated with this issue.

For more information, the FDA has further details

here.